1. SAT0097 Success in osteoarthritis (oa) trial: celecoxib significantly reduces the risk of upper gastrointestinal (ugi) hospitalizations compared to diclofenac and naproxen in 13, 274 randomised patients with oa. (1st June 2001) Authors: Goldstein, J; Eisen, G; Bensen, W; Agrawal, N; Singh, G; Pavelka, K; Burke, TA; Chancellor, JVM; Pettitt, AD; Wilson, AM; Fort, J Journal: Annals of the rheumatic diseases Issue: Volume 60(2001)Supplement 1 Page Start: A187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0449 Analysis of the canadian adalimumab post-marketing observational epidemiological study assessing effectiveness in ankylosing spondylitis (complete-as): association between baseline extra articular manifestations and patient-reported outcomes. (15th June 2017) Authors: Bessette, L; Haraoui, B; Khraishi, M; Bensen, W; Remple, VP Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 656 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0053 Success-1 in osteoarthritis (oa) trial: celecoxib significantly reduces risk of serious upper gi complications compared to nsaids while providing similar efficacy in 13, 274 randomised patients. (1st June 2001) Authors: Singh, G; Goldstein, J; Bensen, W; Agrawal, N; Eisen, G; Fort, J; Bello, A; Boots, S Journal: Annals of the rheumatic diseases Issue: Volume 60(2001)Supplement 1 Page Start: A165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗